Internal Medicine, Medical Oncology · Indianapolis, IN
NPI
1538508965
Since 2013
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
7979 N Shadeland Ave Ste 200
Indianapolis, IN, 46250
Phone (317) 621-4300
Groups this clinician bills Medicare through
Medicare paid, 2024
$100K
1,379 services
Medicare patients, 2024
456
Average age 74
Drug cost, 2024
$5.8M
1,574 prescriptions
Company payments, 2025
$15K
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel W Sonnenburg was code 99214 (office e&m - established), 343 times for 174 patients. In total Daniel W Sonnenburg billed 1,379 services in 12 codes, and Medicare paid $100K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-09-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 343 | 174 | $65.42 | $22K |
| 99232 Hospital E&M - Subsequent | Facility | 262 | 106 | $57.27 | $15K |
| 99215 Office E&M - Established | Facility | 174 | 110 | $101.20 | $18K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 159 | 128 | $11.95 | $1,899 |
| 99233 Hospital E&M - Subsequent | Facility | 117 | 51 | $86.41 | $10K |
| 99204 Office E&M - New | Facility | 95 | 95 | $76.96 | $7,311 |
| 99223 Hospital E&M - Initial | Facility | 82 | 73 | $123.05 | $10K |
| 99205 Office E&M - New | Facility | 57 | 57 | $121.86 | $6,946 |
| 99214 Office E&M - Established | Office | 21 | 18 | $86.33 | $1,813 |
| 99205 Office E&M - New | Office | 18 | 18 | $150.06 | $2,701 |
| 99239 Hospital Discharge Management | Facility | 14 | 13 | $84.38 | $1,181 |
| 99215 Office E&M - Established | Office | 12 | 12 | $121.35 | $1,456 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 11 | 11 | $12.23 | $135 |
By year: 2022 $101K for 1,175 services; 2023 $90K for 1,052 services; 2024 $100K for 1,379 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel W Sonnenburg prescribed most often to Medicare patients was Orgovyx (Relugolix), with 137 prescriptions and refills. In total Daniel W Sonnenburg wrote 1,574 Medicare prescriptions that cost $5.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Orgovyx Relugolix | 137 | 137 | 41 | $312K |
| Prochlorperazine Maleate Generic | 127 | 127 | 85 | $1,300 |
| Ondansetron Hcl Generic | 123 | 124 | 90 | $3,003 |
| Dexamethasone Generic | 123 | 124 | 43 | $683 |
| Prednisone Generic | 98 | 123 | 31 | $439 |
| Abiraterone Acetate Generic | 90 | 92 | 27 | $279K |
| Lynparza Olaparib | 84 | 84 | 19 | $1.0M |
| Nubeqa Darolutamide | 70 | 70 | 15 | $897K |
| Xarelto Rivaroxaban | 62 | 165 | 26 | $85K |
| Eliquis Apixaban | 55 | 140 | 22 | $77K |
| Acyclovir Generic | 44 | 74 | 15 | $420 |
| Lenalidomide Generic | 29 | 29 | Under 11 | $402K |
| Letrozole Generic | 25 | 59 | Under 11 | $537 |
| Gabapentin Generic | 25 | 25 | Under 11 | $249 |
| Erleada Apalutamide | 24 | 24 | Under 11 | $274K |
Brand drugs: 597 claims; generic drugs: 977 claims; opioid claims: 46.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel W Sonnenburg $15K ($15K in general payments such as food, travel and fees) from 10 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $14K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.